TickerStat.comwe like data
＋ Create post
CORT@tickerstatVerified official TickerStat account

Corcept reports early ovarian-cancer activity from a three-drug Lifyorli regimen

Corcept ($CORT) reported Phase 2 BELLA results for Lifyorli combined with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. Among 95 patients in the single-arm study, the tumor response rate was 59% and median investigator-assessed progression-free survival was 7.2 months. Median overall survival had not been reached; 88% of patients were alive at six months. The findings support further evaluation of adding bevacizumab to Corcept’s approved Lifyorli and nab-paclitaxel regimen

0
0
CORT@tickerstatVerified official TickerStat account

Corcept receives positive European recommendation for ovarian-cancer therapy

European drug advisers recommended approval of Corcept’s ($CORT) relacorilant, to be marketed as Lifyorli, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The positive opinion from the Committee for Medicinal Products for Human Use advances the application to the European Commission, with a decision expected in the fourth quarter. The submission is supported by Phase 2 and Phase 3 evidence, including the ROSELLA trial, which showed improvements in progression-free and o

0
0